Literature DB >> 1395992

Effects of interferon-alpha therapy on serum and liver HBV DNA in patients with chronic hepatitis B.

S V Feinman1, B Berris, R Sooknanan, B Fernandes, S Bojarski.   

Abstract

The aim of this study was to evaluate the effect of interferon-alpha therapy on serum and liver HBV DNA in 20 patients with chronic hepatitis B and to correlate the presence or absence of HBV DNA with the clinical response. There were 11 responders and all lost HBV DNA from the serum. Ten of the 11 were followed for 36 months following IFN treatment and remained well with absence of HBeAg and HBV DNA from the serum and with normal ALT. Five also lost HBsAg. HBV DNA became undetectable in the liver of nine of 10 of these patients in whom liver tissue was available for study. HBV DNA persisted in the liver of seven of nine nonresponders and was not detected in two in spite of the presence of HBV DNA and HBeAg in the serum of these two patients. We conclude that IFN may induce long remissions in patients with chronic hepatitis B with loss of HBV DNA from the serum and that occasionally HBV DNA may persist in the liver of such patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1395992     DOI: 10.1007/bf01296489

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside.

Authors:  G H Scullard; L L Andres; H B Greenberg; J L Smith; V K Sawhney; E A Neal; A S Mahal; H Popper; T C Merigan; W S Robinson; P B Gregory
Journal:  Hepatology       Date:  1981 May-Jun       Impact factor: 17.425

2.  Rapid transfer of DNA from agarose gels to nylon membranes.

Authors:  K C Reed; D A Mann
Journal:  Nucleic Acids Res       Date:  1985-10-25       Impact factor: 16.971

3.  Long-term remission of chronic hepatitis B after alpha-interferon therapy.

Authors:  J Korenman; B Baker; J Waggoner; J E Everhart; A M Di Bisceglie; J H Hoofnagle
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

4.  Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication.

Authors:  A S Lok; I V Weller; P Karayiannis; D Brown; M J Fowler; J Monjardino; H C Thomas; S Sherlock
Journal:  Liver       Date:  1984-02

5.  The hepatitis B carrier state--a follow-up study of 100 consecutive cases.

Authors:  Y I Kim; J Heathcote; I R Wanless
Journal:  Clin Invest Med       Date:  1987-09       Impact factor: 0.825

6.  Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers. Correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy.

Authors:  A M Di Bisceglie; J G Waggoner; J H Hoofnagle
Journal:  Gastroenterology       Date:  1987-12       Impact factor: 22.682

7.  Pilot study of recombinant human alpha-interferon for chronic type B hepatitis.

Authors:  J S Dooley; G L Davis; M Peters; J G Waggoner; Z Goodman; J H Hoofnagle
Journal:  Gastroenterology       Date:  1986-01       Impact factor: 22.682

8.  Identification and transmission of hepatitis B virus-related variants.

Authors:  J R Wands; Y K Fujita; K J Isselbacher; C Degott; H Schellekens; M C Dazza; V Thiers; P Tiollais; C Brechot
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

9.  Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum.

Authors:  C M Chu; P Karayiannis; M J Fowler; J Monjardino; Y F Liaw; H C Thomas
Journal:  Hepatology       Date:  1985 May-Jun       Impact factor: 17.425

10.  Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis.

Authors:  J H Hoofnagle; G M Dusheiko; L B Seeff; E A Jones; J G Waggoner; Z B Bales
Journal:  Ann Intern Med       Date:  1981-06       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.